Close

Moleculin Biotech (MBRX) Reports Polish Approval for Leukemia Clinical Trial

December 21, 2017 8:36 AM EST Send to a Friend
Moleculin Biotech, Inc., (NASDAQ: MBRX) a clinical stage pharmaceutical company focused on the development of anti-cancer drug candidates, some of ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login